This article unites the latest guidelines on the management of arterial hypertension in primary health care in Portuguese speaking countries including Brazil, Angola, Mozambique, São Tomé e Príncipe, Cape Verde, among others.
This study aimed to estimate the proportion of Mozambicans eligible for pharmacological treatment for hypertension according to single risk factor and total cardiovascular risk approaches. It concluded that a total of 19.8% of 40–64-year-olds would be eligible for pharmacological treatment of hype...rtension according to the WHO guidelines, all of whom had SBP/DBP at least 160/100 mmHg.
more
Standard Treatment Guideline
Lancet 2012; 380: 611–19
Series: Hypertension 3
CARDIOVASCULAR AFRICA JOURNAL OF AFRICA
Volume 27, No 4, July/August 2016
Primary care health centers and providers who care for individuals with hypertension and cardiovascular disease have an important role to play in ensuring continued access to care, reducing the risk of coronavirus infection, and appropriately managing people with these co-morbidities who acquire COV...ID-19. This guidance includes these considerations
more
based on information as at 28 February 2021
Rapid Policy Brief Series Series 14: COVID-19 and hypertension
Sur la base des informations disponibles au 28 février 2021
Rapid Policy Brief Series Series 14: COVID-19 and hypertension
second edition
Included more self-measured blood pressure (SMBP)-focused content with tools and resources.
Showcased more tools to find patients with potentially undiagnosed HTN.
Added new strategies that focus on chronic kidney disease testing and identification.
Guía de Práctica Clínica para el manejo de la hipertensión arterial primaria (HTA)
Vía Clínica de Hipertensión
This report compiles data for the first time on the far-reaching consequences of uncontrolled hypertension, including heart attacks, strokes and premature death, along with substantial economic losses for communities and countries. It also contains information on the global, regional and country-lev...el burden of hypertension and progress of control efforts.
more
Background
Access to medicines is important for long‐term care of cardiovascular diseases and hypertension. This study provides a cross‐country assessment of availability, prices, and affordability of cardiovascular disease and hypertension medicines to identify areas for improvement in access ...to medication treatment.
Methods and Results
We used the World Health Organization online repository of national essential medicines lists (EMLs) for 53 countries to transcribe the information on the inclusion of 12 cardiovascular disease/hypertension medications within each country's essential medicines list. Data on availability, price, and affordability were obtained from 84 surveys in 59 countries that used the World Health Organization's Health Action International survey methodology. We summarized and compared the indicators across lowest‐price generic and originator brand medicines in the public and private sectors and by country income groups. The average availability of the select medications was 54% in low‐ and lower‐middle‐income countries and 60% in high‐ and upper‐middle‐income countries, and was higher for generic (61%) than brand medicines (41%). The average patient median price ratio was 80.3 for brand and 16.7 for generic medicines and was higher for patients in low‐ and lower‐middle‐income countries compared with high‐ and upper‐middle‐income countries across all medicine categories. The costs of 1 month's antihypertensive medications were, on average, 6.0 days’ wage for brand medicine and 1.8 days’ wage for generics. Affordability was lower in low‐ and lower‐middle‐income countries than high‐ and upper‐middle‐income countries for both brand and generic medications.
Conclusions
The availability and accessibility of pharmaceuticals is an ongoing challenge for health systems. Low availability and high costs are major barriers to the use of and adherence to essential cardiovascular disease and antihypertensive medications worldwide, particularly in low‐ and lower‐middle‐income countries.
more
The World Health Organization (WHO) released its first-ever report on the devastating global impact of high blood pressure, along with recommendations on the ways to win the race against this silent killer. The report shows approximately 4 out of every 5 people with hypertension are not adequately t...reated, but if countries can scale up coverage, 76 million deaths could be averted between 2023 and 2050.
more
Founded in 1977, the Southern African Hypertension Society promotes the common interests of the members of the Society, being persons and organisations concerned with the study and treatment of hypertension. The Society is committed to the maintenance of the highest professional and ethical standard...s in clinical practice and research and in all its affairs and activities. The Society strongly endorses internationally recognised human rights standards, particularly in medical practice and research as set out in the Declaration of Tokyo, 1975 and the Declaration of Helsinki, 2008. The Society is opposed to all forms of discrimination on the grounds of nationality, race, religion or sex. The Society was registered as a non-profit company in South Africa in 2002.
more
Brochure about high blood pressure for patients
Follow-up care is crucial but challenging for disease management particularly in rural areas with limited healthcare resources and clinical capacity, yet few studies have been conducted from the perspective of rural primary care physicians (PCPs). We assessed the frequency of follow-up care delivere...d by rural PCPs for hypertension and type 2 diabetes – the two most common long-term conditions.
more